PM

Piyush Manharlal Ajmera

Active Director Director DIN 02366873
DIN 02366873 First appointment Nov 2009 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 3 historical roles
Total affiliations 6 Since Nov 2009
Shareholding value •••• Premium profile

About Piyush Manharlal Ajmera

Data last updated:

Piyush Manharlal Ajmera is a Director at Dpb Pharmaceuticals Limited (since 2018), Director at Vardhman Chemtech Limited (since 2021) and Director at Dpb Antibiotics Private Limited (since 2010). The companies operate in Pharma. The 3 current companies with reported revenue have a combined latest revenue of ₹432 Cr; the largest is Dpb Pharmaceuticals Limited at ₹223 Cr (FY 2024). Earlier, Piyush Manharlal Ajmera was a Director at Kinvan Private Limited (2020–2024) and Director at Bodhitree Life Sciences Limited (from 2020) and 1 more.

DIN 02366873
Primary Designation Director
Industry Pharma
First Appointment 21 Nov 2009
Oldest Company Age 30 yrs
Largest company Dpb Pharmaceuticals Limited · ₹223 Cr (FY 2024)
Combined revenue ₹432 Cr across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Dpb Pharmaceuticals Limited U24304MH2018PLC308316
Director20 Apr 20182018₹223 Cr (FY 2024)Active
Vardhman Chemtech Limited U24117CH1996PLC018656
Director02 Feb 20211996₹209 Cr (FY 2025)Active
Dpb Antibiotics Private Limited U51397CH2010PTC046352
Director27 Mar 20102010₹10,000 (FY 2024)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Kinvan Private Limited U24100HP2020PTC011851
Director10 Oct 20202020₹136 Cr (FY 2025)Active
Bodhitree Life Sciences Limited U33119PB2020PLC051477
Director24 Jul 20202020Strike Off
Parth Antibiotics Private Limited U51397MH2009PTC197201
Director21 Nov 20092009₹3.13 Cr (FY 2020)Amalgamated

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Piyush Manharlal Ajmera

Directorship timeline

Open interactive timeline →
Vardhman Chemtech Limited
Dpb Pharmaceuticals Limited
Bodhitree Life Sciences Limited
Parth Antibiotics Private Limited
Premium access

Shareholding and investment profile for Piyush Manharlal Ajmera

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Piyush Manharlal Ajmera

Piyush Manharlal Ajmera currently holds 3 directorships: Dpb Pharmaceuticals Limited (Director, since 20 Apr 2018, revenue ₹223 Cr (FY 2024)); Vardhman Chemtech Limited (Director, since 02 Feb 2021, revenue ₹209 Cr (FY 2025)); Dpb Antibiotics Private Limited (Director, since 27 Mar 2010, revenue ₹10,000 (FY 2024)).

Piyush Manharlal Ajmera was first appointed on 21 Nov 2009 as Director at Parth Antibiotics Private Limited. The most recent appointment on record is 02 Feb 2021 at Vardhman Chemtech Limited.

The 3 current companies of Piyush Manharlal Ajmera that report revenue have a combined latest revenue of ₹432 Cr: Dpb Pharmaceuticals Limited ₹223 Cr (FY 2024); Vardhman Chemtech Limited ₹209 Cr (FY 2025); Dpb Antibiotics Private Limited ₹10,000 (FY 2024).

Piyush Manharlal Ajmera held 3 earlier board appointments: Kinvan Private Limited (Director, 10 Oct 2020 to 08 Aug 2024); Bodhitree Life Sciences Limited (Director, from 24 Jul 2020); Parth Antibiotics Private Limited (Director, from 21 Nov 2009).

The current boards of Piyush Manharlal Ajmera's companies include Bhavin Manharlal Ajmera (Dpb Pharmaceuticals Limited), Devang Manharlal Ajmera (Dpb Pharmaceuticals Limited), Sharvan Bhatt (Vardhman Chemtech Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available